@article{Morales_D-2020_7561,
title = {Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis},
author = {Morales, D. and Conover, M. and You, S. and Pratt, N. and Kostka, K. and Duarte-Salles, T. and Fernández-Bertolín, S. and Aragón, M. and DuVall, S. and Lynch, K. and Falconer, T. and van Bochove, K. and Sung, C. and Matheny, M. and Lambert, C. and Nyberg, F. and Alshammari, T. and Williams, A. and Park, R. and Weaver, J. and Sena, A. and Schuemie, M. and Rijnbeek, P. and Williams, R. and Lane, J. and Prats-Uribe, A. and Zhang, L. and Areia, C. and Krumholz, H. and Prieto-Alhambra, D. and Ryan, P. and Hripcsak, G. and Suchard, M.},
month = {dec},
year = {2020},
abstract = {Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational studies so far have lacked rigorous ascertainment adjustment and international generalisability. We aimed to determine whether use of ACEIs or ARBs is associated with an increased susceptibility to COVID-19 in patients with hypertension.},
pages = {98-114},
volume = {3},
issue = {2},
journal = {The Lancet Digital Health},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S2589-7500(20)30289-2},
}
